Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 546,840 |
|
|||||
| News | - | ||||||
| Day High | 4.93 | Low High |
|||||
| Day Low | 4.62 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Alector Inc | ALEC | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.25 | -5.07% | 4.68 | 23:00:03 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.82 | 4.62 | 4.93 | 4.68 | 4.93 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,714 | 546,840 | US$ 4.73 | US$ 2,586,609 | - | 3.66 - 9.065 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:10:07 | 2 | US$ 4.48 | USD |
Alector Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 448.11M | 95.75M | - | 97.06M | -130.39M | -1.36 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Alector News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALEC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.36 | 5.00 | 4.235 | 4.55 | 704,153 | 0.32 | 7.34% |
| 1 Month | 5.50 | 5.62 | 4.235 | 4.92 | 737,024 | -0.82 | -14.91% |
| 3 Months | 6.21 | 6.25 | 4.235 | 5.31 | 584,312 | -1.53 | -24.64% |
| 6 Months | 7.876 | 8.90 | 4.235 | 6.18 | 666,442 | -3.20 | -40.58% |
| 1 Year | 7.69 | 9.065 | 3.66 | 6.16 | 657,450 | -3.01 | -39.14% |
| 3 Years | 20.21 | 43.32 | 3.66 | 14.19 | 698,927 | -15.53 | -76.84% |
| 5 Years | 20.70 | 45.00 | 3.66 | 15.90 | 651,542 | -16.02 | -77.39% |
Alector Description
| Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101. |
